Document:

LICENSE AGREEMENT

      This LICENSE  AGREEMENT  (the  "Agreement")  is made and entered into this
25th day of October, 2005 among Mark Froimowitz, residing at 90 Eastbourne Road,
Newton, Massachusetts 02159, ("Licensor") and DNAPRINT PHARMACEUTICALS,  INC., a
corporation  organized  and  existing  under the laws of  Florida  and having an
address at 900 Cocoanut Avenue, Sarasota, FL 34236 ("Licensee").

      WHEREAS,  Licensor is an inventor and owner of the entire right, title and
interest in and to the compounds  described in Exhibit A (the  `Compounds")  and
all Patent Rights with respect thereto;

      WHEREAS, Licensor desires to grant an exclusive license to Licensee of all
Patent Rights and other intellectual property associated with the Compounds, and
Licensee desires to receive such a license;

      NOW, THEREFORE,  in consideration of the mutual undertakings and covenants
contained  herein and other good and  valuable  consideration,  the  receipt and
sufficiency  of which are  hereby  acknowledged,  the  Parties  hereto  agree as
follows:

      1.  Licensor  Rights.  Licensor  represents  and warrants  that the Patent
Rights and other rights  covered  hereby are jointly owned by him and Charles J.
Kelley  ("Kelley") also an inventor,  that Kelley has granted  Licensor the full
and  unrestricted  right to enter into this License  Agreement  and to grant the
licenses and rights provided for herein,  which licenses and rights apply to the
entirety of the Patent Rights and other rights covered hereby, without regard to
any interest  owned by Kelley.  Licensor  hereby  represents  and warrants  that
Kelley has agreed to be bound by the terms of this License Agreement,  including
the exclusive license granted hereby and that the term "Licensor" as used herein
shall include Kelley.

      2. Definitions.  As used in this Agreement,  the following terms,  whether
used in the singular or plural, shall have the following meanings:

            2.1 "Affiliate" means any corporation,  company, partnership,  joint
venture and/or firm which controls,  is controlled by or is under common control
with Licensee.  For purposes of this Section 2.1,  "control" shall include,  but
not be limited  to, (a) in the case of  corporate  entities,  direct or indirect
ownership of over fifty  percent  (50%) of the stock or shares  entitled to vote
for the election of  directors;  and (b) in the case of  noncorporate  entities,
direct  or  indirect  ownership  of fifty  percent  (50%) or more of the  equity
interest  with  the  power  to  direct  the  management  and  policies  of  such
noncorporate  entities.  The term  "Affiliate"  shall also  include  any firm or
entity in which Licensee holds an equity interest of 25% or more.

            2.2 "Improvements"  means and shall include any inventions  relating
to the Compounds in the Field owned or invented by Licensor which would infringe
one  or  more  claims  maintained  in  good  faith  in a  United  States  patent
application or an unexpired or nonlapsed patent included in the Patent Rights.

<PAGE>

            2.3  "Field"  means  all uses or  potential  uses of the  Compounds,
including all therapeutic, diagnostic, and prophylactic uses.

            2.4  "Product  Candidate"  means  each  product  candidate  which is
covered by a Valid Claim included in the Patent Rights, and selected by Licensee
for use in clinical testing.

            2.5   "Licensed   Products"   means  any   product  or  process  the
manufacture,  use or sale of which is covered by or subject to a Valid  Claim of
any of the  Patent  Rights in the  country  where  such  product is sold or such
process is practiced.

            2.6 "Net Sales"  shall mean the gross  amount  actually  received by
Licensee,   its  Affiliates,   or  sublicensees  from  sales  by  Licensee,  its
Affiliates,  or sublicensees of Licensed Products, less: (i) returns, credits or
allowances,  if any, actually granted;  (ii) discounts  actually allowed;  (iii)
retroactive price reductions;  (iv) freight,  postage, and insurance charges and
additional special packaging charges; (v) customs duties and (vi) excises, sales
taxes,  duties or other taxes  imposed  upon and paid with respect to such sales
(excluding  what is commonly  known as income tax).  Net Sales shall not include
any transfer between  Licensee and its Affiliates for resale,  but shall include
the resale by Licensee or an Affiliate.

            2.7 "Party" means Licensor or Licensee; "Parties" means Licensor and
Licensee.

            2.8 "Patent Rights" means all patents and patent applications (which
for all purposes of this Agreement  shall be deemed to include  certificates  of
invention,  applications  for  certificates  of  invention  and utility  models)
throughout  the world,  covering  or relating to the  Compounds,  including  any
substitutions, extensions or supplementary protection certificates of, reissues,
reexaminations,  renewals,  divisions,  continuations or  continuations-in-part,
which Licensor owns or controls,  or under which Licensor has the right to grant
sublicenses to Licensee.

            2.9 "Technology  Rights" means all information owned or possessed by
Licensor,  together with all improvements,  discoveries,  methods,  processes or
developments,  whether patentable or otherwise, relating to the Compounds, which
is necessary  for  Licensee to develop,  manufacture,  use and/or sell  Licensed
Products hereunder.

            2.10 "Valid Claim" means a claim of any  unexpired  United States or
foreign patent or any subsisting  patent  application  which shall not have been
withdrawn,  canceled or  disclaimed,  nor held  invalid by a court of  competent
jurisdiction in an unappealed or unappealable decision.

                                       2
<PAGE>

      3. License Grant

            3.1  Representations.  Licensor  represents and warrants that he has
the  right  to  enter  into  this  License  Agreement;  and he has the  full and
unrestricted right to grant the licenses and rights provided for herein.

            3.2  License.  Licensor  hereby  grants  to  Licensee  the  sole and
exclusive, worldwide license, including the right to sublicense others under the
Patent  Rights  and  the  Technology  Rights  in the  Field,  including  without
limitation  the right to make,  have made,  use,  sell or  otherwise  dispose of
Licensed Products.  Any and all Improvements  conceived after the Effective Date
hereof  shall be  included in the Patent  Rights and be subject to the  payments
called for in Section 4, hereof.

            3.3 Assistance. Licensor shall provide Licensee with all information
directly  related to the Patent Rights and Technology  Rights as may be known or
possessed by Licensor and as may be reasonably necessary for Licensee to exploit
the licenses granted in Section 3.2.

            3.4 Limitation. The license rights granted hereunder shall terminate
in the event of a default by Licensee in its  obligations to Licensor  hereunder
which is not cured within 90 days after receipt by Licensee of detailed  written
notice of such default.

            3.5  Improvements.  Licensor  shall  provide  Licensee  with written
notification  of each  Improvement  and a  description  thereof  sufficient  for
Licensee  to  understand,  evaluate,  and  consider  such  Improvement,  and  if
possible, sufficient to enable preparation of a patent application thereon. Such
notice from  Licensor  to  Licensee  shall be made  promptly  after  Licensor or
persons acting on behalf of Licensor have reduced such  Improvement to practice,
but in any  event,  shall  be  made at  least  thirty  (30)  days  prior  to any
publication of nonconfidential disclosure thereof.

      4. License Fees and Royalties:  Licensee shall make the following payments
to Licensor:

            4.1 License  Maintenance  Fees.  Upon  execution of this  Agreement,
Licensee shall pay $10,000 to patent counsel designated by Licensor. Thereafter,
Licensee  shall pay Licensor  $25,000 on the annual  anniversary of execution of
this  Agreement for each of 2006,  2007,  2008,  and 2009.  If at any time,  the
United States Patent and Trademark  Office or a court of competent  jurisdiction
declares  that the Patent  Rights are invalid or  unenforceable  in any material
respect,  Licensee, at its option, may terminate this Agreement and cease making
payments  pursuant  to this  Section  4.1.  Upon each of the fifth,  tenth,  and
fifteenth anniversaries of the execution of this Agreement, Licensee may, at its
option,  either (i) terminate this Agreement upon written notice to Licensor, or
(ii)  maintain  this  Agreement  for an  additional  five year term. If Licensee
chooses to maintain this  Agreement for an additional  five year term,  Licensee
shall continue to pay Licensor  $25,000 annually on the anniversary of execution
of this Agreement.  If royalties commence, the $25,000 will be deducted from the
royalties.

                                       3
<PAGE>

      4.2 Royalties.

            (a)   The Licensee shall pay to Licensor, during the applicable term
                  described in Section  4.2(b)  below,  earned  royalties at the
                  rate of two  percent  (2%) on all Net Sales by  Licensee,  its
                  Affiliates,  or sublicensees of Licensed Products covered by a
                  Valid Claim of the Patent Rights.

            (b)   The  obligation  of  Licensee  to pay  royalties  on  sales of
                  Licensed  Products  covered  by a Valid  Claim  of the  Patent
                  Rights shall  terminate on a  country-by-country  basis on the
                  expiration or termination of any applicable  Valid Claim under
                  the  Patent  Rights in the  country  in which the  product  is
                  manufactured, used, or sold. This paragraph is not intended to
                  allow the  transfer  of  Licensed  Products  between a country
                  subject to the foregoing termination and a country not subject
                  to the foregoing termination in derogation or circumvention of
                  Licensor's rights to such royalties.

            4.3  Sublicenses.  The Licensee may grant  sublicenses  hereunder to
persons,  firms or  corporations  under  such  terms  and  conditions  as it may
arrange;  provided,  however,  that such  sublicenses  shall  include all of the
rights  of and  obligations  due to the  Licensor  that  are  contained  in this
Agreement.

            4.4 Reports and Payments.  Licensee shall deliver to Licensor within
forty-five  (45) days after the end of each  calendar  quarter a written  report
showing its  computation of royalties due under this Agreement for such calendar
quarter.  Thirty (30) days after  delivery of each such report,  Licensee  shall
tender payment of all amounts shown to be due thereon.  The royalty payments due
on sales in currencies  other than U.S.  dollars  shall be calculated  using the
appropriate  exchange  rate  for such  currency  quoted  by the Bank of  America
foreign  exchange desk on the close of business on the business day  immediately
preceding the date of such report. All amounts due under this Agreement shall be
paid to Licensor in United Slates  dollars.  During the term of this  Agreement,
Licensor  shall have the right from time to time (not to exceed once during each
calendar year) to inspect, or have an agent,  accountant or other representative
inspect,  during normal business hours, and upon reasonable  advance notice (not
less than 72 hours),  such books,  records and other supporting data of Licensee
or its  Affiliates  as may be  necessary  to verify  Licensee's  computation  of
royalties   due  under  this   Agreement.   Licensor   agrees  to  maintain  the
confidentiality of any information acquired during such inspection or review. If
such  review  shows  that the  Licensor  has failed to pay any  royalties  owed,
Licensee shall promptly remit such  additional  royalties to Licensor,  together
with  interest  at a rate of 10% per  annum  calculated  from  the date any such
payment was due. If such review shows that  Licensee has  understated  royalties
owed  by 10% or  more,  Licensee  shall  reimburse  Licensor  for  the  cost  of
conducting such review.

                                       4
<PAGE>

            4.5 Progress Payments. In addition to the foregoing,  Licensee shall
make the following payments to Licensor:

            (a)   $50,000  upon a  filing  by or on  behalf  of  Licensee  of an
                  Investigational  New Drug  Application  ("IND")  with the U.S.
                  Food and Drug  Administration  (the "FDA")  covering a phase I
                  clinical  trial  of each  Product  Candidate,  and  acceptance
                  thereof by the FDA;

            (b)   $50,000 upon completion of such phase I trial for each Product
                  Candidate;

            (c)   $75,000 upon  completion of a phase II clinical  trial of each
                  Product Candidate pursuit to an IND approved by the FDA; and

            (d)   $100,000  upon  notice of  approval  by the FDA of a  Licensed
                  Product for commercial sale.

      5.  Commercialization.  Licensee or its  assignee  shall use  commercially
reasonable  efforts to  develop  and  commercialize  the  Compounds  in a manner
consistent with reasonable business judgment and product development practice in
the pharmaceutical industry including determining whether (i) it is commercially
feasible to develop a product using the Compounds and (ii) such  development  is
consistent with Licensee's business plans and objectives. If Licensee determines
either  that it is not  commercially  feasible or that such  development  is not
consistent  with  its  business  plans  and  objectives,  the  licenses  granted
hereunder shall terminate.  Licensee,  however,  will still be liable for annual
license  maintenance  fees  for  the  remaining  years  of a five  year  term as
specified in Section 4.1., except for termination as allowed by this Agreement.

      6. Intellectual Property Rights.

            6.1 Right of Licensee to  Prosecute  Applications.  Licensor  agrees
that Licensee shall have the exclusive  right, at Licensee's  expense but in the
name of Licensor to file,  prosecute,  maintain and enforce patent  applications
and  patents  relating  to the  Compounds,  provided  that  Licensee  shall  use
commercially  reasonable  efforts  to  implement  the  foregoing.  Copies of all
substantive  communications to and from patent offices regarding applications or
patents  relating to the Compounds shall be provided to Licensor  promptly after
the receipt  thereof;  copies of  proposed  substantive  communications  to such
patent  offices shall be provided to Licensor in sufficient  time before the due
date in order to enable  Licensor  an  opportunity  to  comment  on the  content
thereof.  Licensee will reasonably  consider such comments but shall be under no
obligation   to   incorporate   Licensor's   comments   into   any   substantive
communications. Licensee shall timely notify Licensor (but in no event less than
30 days prior to the expiration of any priority rights period) if it intends not
to seek patent  protection  on the  Compounds in any country or  territory,  and
Licensor  shall have the right to file,  maintain  and  enforce in such  country
patents  relating to the  Compounds,  and such  patents and patent  applications
shall not be included within the terms of this Agreement.

                                       5
<PAGE>

            6.2 Assistance. Licensor shall provide to Licensee or its authorized
attorneys,  agents or  representatives  reasonable  assistance  as necessary for
Licensee to exploit its right under Section 6.1 to file, prosecute, maintain and
enforce patent applications and patents.  Licenser shall execute or use his best
efforts to have  executed  all legal  documents  necessary  to file,  prosecute,
maintain and enforce patent applications or patents at no charge to Licensee.

            6.3 Third Party Infringement.

            (a)   Each  Party  shall  promptly  report in  writing to each other
                  Party  during  the  term  of  this  Agreement  any  (i)  known
                  infringement  or suspected  infringement  of any of the Patent
                  Rights   in   the   Field   or   (ii)   unauthorized   use  or
                  misappropriation  of the  Technology  Rights in the Field by a
                  third party of which it becomes aware,  and shall provide each
                  other  Party  with  all  available  evidence  supporting  said
                  infringement,  suspected  infringement or unauthorized  use or
                  misappropriation.  Within  ninety  (90)  days  after  Licensee
                  becomes,  or is made, aware of any of the foregoing,  Licensee
                  shall  decide  whether or not to initiate an  infringement  or
                  other  appropriate suit and Licensee shall advise the Licensor
                  of such  decision in  writing.  The  inability  of Licensee to
                  decide on a course  of  action  within  such  ninety  (90) day
                  period  shall  for  purposes  of this  Agreement  be  deemed a
                  decision not to initiate an infringement or other  appropriate
                  suit.

            (b)   Except as provided in paragraph (d) below, Licensee shall have
                  the right to initiate  an  infringement  or other  appropriate
                  suit  anywhere in the world against any third party who at any
                  time has infringed, or is suspected of infringing,  any of the
                  Patent  Rights or of using  without  proper  authorization  or
                  misappropriating  all or any portion of the Technology Rights.
                  Licensee shall give the Licensor  sufficient advance notice of
                  the  intent to file said suit and the  reasons  therefor,  and
                  shall provide Licensor with an opportunity to make suggestions
                  and comments regarding such suit. Licensee shall keep Licensor
                  promptly informed of, and shall from time to time consult with
                  Licensee  regarding,  the  status  of any such  suit and shall
                  provide  Licensor with copies of all  documents  filed in, and
                  all written communications relating to the suit.

                                       6
<PAGE>

            (c)   Licensee  shall  select  counsel  for any suit  referred to in
                  paragraph (b) and shall otherwise fully control such suit, its
                  conduct,  compromise or settlement.  Licensee shall, except as
                  provided  below,  pay all  expenses  of the  suit,  including,
                  without  limitation,  attorneys'  fees and  court  costs.  Any
                  damages,  settlement  fees or  other  consideration  for  past
                  infringement  received as a result of such litigation shall be
                  paid  first to  Licensee,  in  reimbursement  of all  expenses
                  incurred by Licensee in connection  with such suit; any amount
                  remaining  shall  be  allocated  98%  to  Licensee  and  2% to
                  Licensor. If necessary,  Licensor shall join as a party to the
                  suit but shall be under no obligation to participate except to
                  the extent that such  participation  is required as the result
                  of  being a named  party to the  suit.  Licensor  shall  offer
                  reasonable  assistance to Licensee in connection  therewith at
                  no charge to Licensee except for  reimbursement  of reasonable
                  expenses,  including  out-of-pocket  expenses  and salaries of
                  Licensor  personnel,  incurred in rendering  such  assistance.
                  Licensor   shall  have  the  right  to   participate   and  be
                  represented  in any such  suit by its own  counsel  at its own
                  expense.

            (d)   Licensee shall  promptly  advise the Licensor of the intent of
                  Licensee not to initiate an infringement or other  appropriate
                  suit  pursuant  to  paragraph  (b)  above.  In the event  that
                  Licensee   does  not   initiate  an   infringement   or  other
                  appropriate  suit  pursuant to  paragraph  (b) above within 90
                  days  of  becoming  aware  of any  infringement  or  suspected
                  infringement of any of the Patent Rights or  unauthorized  use
                  or misappropriation of any of the Technology Rights by a third
                  party,  or if  Licensee  shall have  advised  Licensor  of the
                  intent  not to  initiate  such suit,  Licensor  shall have the
                  right, at its expense,  of initiating an infringement or other
                  appropriate  suit. In exercising  its rights  pursuant to this
                  paragraph  (d),  Licensor  shall  have the sole and  exclusive
                  right to select counsel and shall pay all expenses of the suit
                  including without limitation  attorneys' fees and court costs.
                  If necessary,  Licensee  shall join as a party to the suit and
                  shall  participate only to the extent that such  participation
                  is required as a result of its being a named party to the suit
                  or being the holder of, or inventor  under any patent at issue
                  or being the  owner of any  Technology  Rights  at  issue.  At
                  Licensor's request, Licensee shall offer reasonable assistance
                  to Licensor in  connection  therewith at no charge to Licensor
                  except for reimbursement of reasonable  out-of-pocket expenses
                  incurred in rendering such  assistance.  Without-limiting  the
                  generality of the preceding sentence, Licensee shall cooperate
                  fully in  order to  enable  Licensor  to have the  right to be
                  represented  in any such  suit by its own  counsel  at its own
                  expense.

                                       7
<PAGE>

            6.4 Claimed Infringement.

            (a)   In the event that a third party at any time  provides  written
                  notice of a claim to, or brings an action,  suit or proceeding
                  against,  any Party or any of their  respective  affiliates or
                  sublicensees,  claiming  infringement  of its patent rights or
                  copyrights  or  unauthorized  use or  misappropriation  of its
                  technology,  based upon an assertion  or claim  arising out of
                  the development, manufacture, use or sale of Licensed Products
                  (a "Claim"),  such Party shall promptly notify the other Party
                  of the  Claim  or the  commencement  of such  action,  suit or
                  proceeding,  enclosing  a copy of the claim  and/or all papers
                  served.

            (b)   Licensee shall have sole and exclusive  responsibility for the
                  selection of counsel and control of any Claim,  and shall keep
                  Licensor informed of the current status of the suit.  Licensor
                  shall   cooperate   with  Licensee  and  give  all  reasonable
                  assistance in connection with the conduct of such suit.

            (c)   In the event that the Claim (whether  pursuant to a settlement
                  of the suit or a final  judgment)  results in an obligation to
                  pay the Third Party a royalty on future  sales of the Licensed
                  Product,  such royalties shall be paid by Licensee and for all
                  purposes of this  Agreement,  such royalties shall be deducted
                  in determining the amount of Net Sales hereunder.

      7.  Publication  Review.  In the case of any  paper,  technical  report or
abstract,  summary or synopsis  thereof intended to be published or presented by
Licensor,  ("paper"), Licensor shall provide Licensee with an advance copy. If a
patent  application  has  already  been  filed with  respect  to all  inventions
described  therein,  Licensor  shall send  Licensee a final form copy thereof at
least  thirty  (30) days  prior to  submission  for  publication  nor any public
disclosure thereof ("disclosure").  In all other cases, Licensor shall, at least
forty five (45) days  prior to  disclosure,  send  Licensee a final form copy of
each paper.  In such cases,  Licensee may require  Licensor to delay making such
proposed disclosure for a maximum of an additional forty five (45) days in order
to protect the potential  patentability of any invention described therein.  (In
the case of non-patentable,  but confidential  information contained in a paper,
the parties shall negotiate an acceptable  version for publication within ninety
(90) days after notification). Licensor shall use his best efforts and cooperate
with Licensee insuring that any improvement or invention in the Field identified
by  Licensee  in  such  paper  or  report  is  filed  by  Licensor  as a  patent
application.

                                       8
<PAGE>

      8.  Liability  Insurance.  No later  than the first  commercial  sale of a
Licensed  Product,  Licensee shall carry a product  liability  insurance  policy
protecting  the Licensor with respect to such  Licensed  Product in an amount of
not less than five million dollars ($5,000,000) per occurrence with a minimum of
an aggregate of ten million dollars  ($10,000,000) for personal injury or death.
Notwithstanding the foregoing, Licensee shall only be obligated to purchase such
insurance to the extent that it is available at commercially reasonable rates.

      9. Warranty.  Except as otherwise  expressly set forth in this  agreement,
Licensor makes no representations  and extends no warranties of any kind, either
express or implied, including but not limited to warranties of merchant ability,
fitness for a particular purpose,  and validity of patent rights claims,  issued
or pending.  Nothing in this  agreement  shall be construed as a  representation
made or warranty  given by Licensor that the practice by Licensee of the License
granted hereunder shall not infringe the patent rights of any third party.

      10. Term and  Termination.  This Agreement shall terminate on the later of
(a) the twentieth (20th) anniversary hereof or (b) the date of the expiration of
the last to expire Valid Claim under the Patent Rights.

      11.  Assignment.  Licensee  may not  assign  its  rights  and  obligations
hereunder  without  written  consent  of  Licensor,  which  consent  will not be
unreasonably  withheld.  Notwithstanding  the  foregoing,  Licensee  may  assign
hereunder to persons,  firms or corporations  under such terms and conditions as
it may arrange;  provided,  however,  that such assignment  transfers all of the
rights of and  obligations due to Licensor that are contained in this Agreement;
and further provided,  however,  that if Licensee receives any consideration for
such  assignment,  Licensor  will  receive  the lesser of (a)  $100,000,  or (b)
one-half  of such  consideration  if such  consideration  is valued at less than
$100,000.

      12. Notice.

      All notices and payments required or permitted to be given hereunder shall
be in writing and addressed to the respective parties as follows;

         If to Licensor:            Mark Froimowitz. Ph.D
                                    90 Eastbourne Road
                                    Newton, Massachusetts 02159

         If to Licensee:            DNAPrint Pharmaceuticals, Inc.
                                    900 Cocoanut Ave.
                                    Sarasota, FL  34236
                                    Attention: Richard Gabriel

         With a copy to:            Thomas P. McNamara, Esq.
                                    Thomas P. McNamara, P.A.
                                    2909 Bay to Bay Blvd., Ste. 309
                                    Tampa, FL  33629

                                       9
<PAGE>

or such  other  addresses  as may be  designated  by the  respective  parties in
writing.  A notice shall be deemed  given the earlier of the date when  actually
received  or five (5) days  after  deposit in the United  Stares  registered  or
certified mail, postage prepaid, and properly addressed.

      13. Section Headings.  Section headings are for convenience only and shall
not be  construed  to limit or extend the meaning of any portion of this License
Agreement.

      14. Law  Governing  and  Construction.  This  License  Agreement  shall be
governed by and construed in  accordance  with the laws of the  Commonwealth  of
Massachusetts  as if the Agreement had been delivered in  Massachusetts  and all
acts which are done or are  required  to be done  hereunder  were all  performed
within the  Commonwealth  of  Massachusetts.  This  License  Agreement  has been
drafted  on the  basis  of  mutual  understanding  and  neither  party  shall be
prejudiced as being the drafter thereof.

      15. Entire  Agreement,  Modification,  Etc. This  instrument  contains the
entire and only  agreement  between the parties  relative to the subject  matter
hereof and supersedes all previous negotiations,  representations,  undertakings
and agreements  both written and oral  heretofore made between the parties as to
the subject  matter.  Any  representation,  promise or condition  in  connection
herewith not specifically  incorporated  herein shall not be binding upon either
party. The provisions of this agreement may not be explained,  supplemented,  or
qualified  through evidence of custom,  trade usage or prior course of dealings.
No modification, renewal, extension, waiver, cancellation or termination of this
Agreement or of any of the provisions  herein contained shall be valid until and
unless  made in writing and signed on behalf of the  respective  parties by duly
authorized officers thereof.

      16.  Severability.  If any provisions of this License  Agreement  shall be
construed  to be illegal or invalid,  the  legality or the validity of any other
provisions  hereof  shall  not be  affected  thereby.  Any  illegal  or  invalid
provision of this License Agreement shall be severable, and all other provisions
shall remain in full force and effect.

      IN WITNESS WHEREOF,  the parties have entered into this License  Agreement
as of the date first above written.

DNAPrint Pharmaceuticals, Inc.

By:/s/ Richard Gabriel                               /s/ Mark Froimowitz
   ----------------------------                      ---------------------------
                                                     Mark Froimowitz. Ph.D

                                       10Walker Financial Corporation 6% Promissory Note

Dated: August 5, 2004 Principal Amount: $125,000.00 Garden City, New York

For Value Received, the undersigned, Walker Financial Corporation (together with
its successors and assigns, "Walker"), a Delaware corporation, hereby promises
to pay to Cindy Dolgin, an individual residing in the State of New York
("Lender"), the principal sum of One Hundred Twenty Five Thousand Dollars
($125,000.00), together with interest as set forth below.

1. Interest Rate. Until an event of Default shall have occurred, the principal
amount evidenced by this Note shall bear interest at the rate of 6% per annum,
computed on the basis of a 360-day year for the actual number of days elapsed
(the "Applicable Interest Rate"). Upon the occurrence of an event of Default,
the outstanding principal amount and any accrued but unpaid interest thereon
shall bear interest until paid at the Applicable Interest Rate plus an
additional 2% per annum (the "Default Interest Rate").

2. Payment Date; Payment Method; Prepayment.

(a) Payment Dates. Payment of all accrued and unpaid interest due under this
Note shall be payable at the maturity of the loan which will be 60 days after
the effectiveness of Walker's Registration Statement or 150 days whichever is
shorter (hereinafter the "Maturity Date"). Upon payment in full of the principal
evidenced by this Note (and any accrued but unpaid interest thereon), Lender
shall mark this Note "CANCELLED" and return this Note as so marked to Walker
within five days after such payment in full is confirmed.

(b) Payment Method. Payment of the principal evidenced by this Note (and any
accrued but unpaid interest thereon) shall be made by check or wire transfer of
immediately available funds to an account designated by Lender.

(c) Voluntary Prepayment. Walker may pay, without penalty or premium, the
principal amount evidenced by this Note (and any accrued but unpaid interest
thereon), in whole or part, at any time up to the Maturity Date upon no less
than five day's prior notice to Lender. Any partial prepayment shall first be
applied against any accrued and unpaid interest due under this Note and then to
the principal amount evidenced by this Note. In the event of a voluntary
prepayment being less than the full amount outstanding under this Note
(including any accrued but unpaid interest), upon surrender of this Note in
connection with said partial prepayment, Walker shall deliver to Lender a new
note substantially in the form of this Note and evidencing as principal any
amount not so prepaid.

3. Default; Acceleration.

(a) Any of the following shall constitute an event of Default under this Note:

(i) the failure by Walker to pay any amounts required to be paid under this Note
on or before the date on which such payment was due;

(ii) the breach or noncompliance by Walker of any of its representations,
warranties or covenants contained in the Loan Agreement;

(iii) Walker shall (A) apply for or consent to the appointment of a receiver or
trustee of Walker's assets;

<PAGE>

(B) make a general assignment for the benefit of creditors;

(C) file a petition or other request no matter how denominated ("Petition")
seeking relief under Title 11 of the United States Code or under any other
federal or state bankruptcy, reorganization, insolvency, readjustment of debt,
dissolution or liquidation law or statute ("Bankruptcy Statute"); or

(D) file an answer admitting the material allegations of a Petition filed
against it in any proceeding under any Bankruptcy Statute;

(iv) there shall have entered against Walker an order for relief under any
Bankruptcy Statute; or

(v) a Petition seeking an order for relief under any Bankruptcy Statute is filed
by any one other than Walker and without Walker's consent or agreement which is
not dismissed or stayed within 60 days after the date of such filing, or such
Petition is not dismissed upon the expiration of any stay thereof.

(b) Upon the occurrence of an event of Default, the unpaid principal amount
evidenced by this Note (and any accrued but unpaid interest thereon) shall be
immediately due and payable.

(c) Until the occurrence of an event of Default, the principal amount evidenced
by this Note shall bear interest at the Applicable Interest Rate and upon an
event of Default, any unpaid principal amount and any accrued but unpaid
interest thereon under this Note shall bear interest until paid at the Default
Interest Rate.

4. Enforcement. All disputes regarding the enforcement or construction of this
Note shall be resolved in accordance with the Loan Agreement and may not be
resolved independently of the enforcement or construction of the Loan Agreement
which has been made a part hereof.

5. Assignment. This Note is not assignable by Walker, and any purported
assignment of this Note shall be null and void and of no effect.

6. Governing Law. This Note and all rights and obligations hereunder shall be
governed by and construed in accordance with the laws of the State of New York
applicable to agreements made and be performed wholly within such State, without
regard to such State's conflicts of laws principles.

7. Notices. All requests, demands, notices and other communications required or
otherwise given under this Agreement shall be sufficiently given if (a)
delivered by hand against written receipt therefor, (b) forwarded by overnight
courier requiring acknowledgment of receipt or (c) mailed by postage prepaid,
registered or certified mail, return receipt requested, addressed as follows:

If to Walker, to:                  Mitchell Segal, President
                                   Walker Financial Corporation
                                   990 Stewart Avenue
                                   Suite 60A
                                   Garden City, New York 11530

                                        2
<PAGE>

If to Lender, to:                  Mrs. Cindy Dolgin
                                   3 Jordan Drive
                                   Great Neck, N.Y. 11021

or, in the case of any of the parties hereto, at such other address as such
party shall have furnished in writing, in accordance with this Section 8, to the
other parties hereto. Each such request, demand, notice or other communication
shall be deemed given (a) on the date of delivery by hand, (b) on the first
business day following the date of delivery to an overnight courier or (c) three
business days following mailing by registered or certified mail.

IN WITNESS WHEREOF, the parties have executed or caused to be executed this Note
as of the date first above written.

                                               Walker Financial Corporation

By:    /s/ Mitchell Segal
       -------------------------
       Mitchell Segal, President

                                        3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]